Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Lung Neoplasms 3Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Sarcoma 1

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Docetaxel 70Carboplatin 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × zimberelimab × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04772989 2025-08-28

ARC-12

Arcus Biosciences, Inc.

Phase 1 Completed
94 enrolled
DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡